Fort Sheridan Advisors LLC Purchases 23,000 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Fort Sheridan Advisors LLC raised its position in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 71.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,177 shares of the company’s stock after buying an additional 23,000 shares during the quarter. Fort Sheridan Advisors LLC’s holdings in Lineage Cell Therapeutics were worth $28,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in LCTX. Red Crane Wealth Management LLC purchased a new stake in shares of Lineage Cell Therapeutics during the 4th quarter valued at about $171,000. Atria Wealth Solutions Inc. purchased a new stake in Lineage Cell Therapeutics during the fourth quarter valued at approximately $29,000. Defender Capital LLC. lifted its stake in shares of Lineage Cell Therapeutics by 19.2% in the 4th quarter. Defender Capital LLC. now owns 5,963,348 shares of the company’s stock valued at $2,997,000 after purchasing an additional 961,150 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Lineage Cell Therapeutics by 35.5% in the 4th quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after purchasing an additional 18,053 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Lineage Cell Therapeutics by 13.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 677,162 shares of the company’s stock worth $613,000 after purchasing an additional 82,864 shares during the period. Institutional investors own 62.47% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on LCTX shares. D. Boral Capital dropped their price target on shares of Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, February 11th. Maxim Group dropped their target price on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a research note on Tuesday, February 11th.

Lineage Cell Therapeutics Stock Performance

LCTX opened at $0.56 on Friday. The firm has a market cap of $123.77 million, a PE ratio of -4.68 and a beta of 1.21. Lineage Cell Therapeutics, Inc. has a 12-month low of $0.48 and a 12-month high of $1.61.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.